MCLEAN, Va., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Acentra Health, a technology and health solutions and services company dedicated to accelerating better outcomes for government healthcare agencies and the priority populations they serve, announced that the Centers for Medicare & Medicaid Services (CMS) has renewed its five-year contract as a Beneficiary and Family Centered Care-Quality Improvement Organization (BFCC-QIO) through April 30, 2029. The renewal of Acentra Health's services to support Medicare ben ...

文章核心观点 - 公司Acentra Health是一家专注于为政府医疗机构和优先服务对象提供技术和健康解决方案的公司 [1] - 公司CEO Todd Stottlemyer连续三年被弗吉尼亚商业杂志评选为弗吉尼亚州最有影响力的领导人之一 [1][2] - 公司在弗吉尼亚州拥有超过3,200名员工,为45个州和25个联邦机构提供服务,是弗吉尼亚州医疗补助服务部(DMAS)的重要合作伙伴 [2][3] 公司概况 - 公司总部位于弗吉尼亚州北部,自2007年起一直为弗吉尼亚州DMAS提供医疗利用管理服务,服务对象为200万弗吉尼亚州民众 [2] - 2023年,DMAS与公司续签了为期5年的新合同,扩大了公司的服务范围,包括行为健康服务的授权 [2] - 公司CEO Stottlemyer在加入公司后,主导了多次收购,使公司的能力得到扩展,全球员工人数也超过了一倍,其中包括300多名在弗吉尼亚州、马里兰州和华盛顿特区地区的员工 [3] 公司领导 - Stottlemyer目前担任弗吉尼亚州增长和机遇(GO)委员会副主席,北弗吉尼亚技术委员会执行委员会成员,并在多个其他董事会任职 [3] - Stottlemyer被认为是饥饿救济和教育的积极倡导者,在2023年被"无饥饿儿童"组织评为"冠军",领导北弗吉尼亚技术界筹集了超过100万美元用于疫情期间儿童在家学习期间的饥饿救助 [3]

TORONTO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. ("Spectral" or the "Company") (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company's Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion ("PMX") in a randomized controlled trial of adults treated for endotoxemia and septic shock. Tigris Enrollment: Robust enrollment into the second half of 2024, which continues the pa ...

sankai Introduction Carlyle Secured Lending (NASDAQ:CGBD) is a business development company that has been one of my favorite smaller cap BDCs for a while. The stock has performed well in a high-interest rate environment, but their portfolio companies have faced some headwinds recently. Additionally, they recently announced a merger with Carlyle Secured Lending III that is expected to provide benefits such as increased liquidity, size and scale for the company moving forward. With the share price experiencin ...

NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Carlyle Credit Income Fund (the "Fund") (NYSE: CCIF), an externally managed closed-end fund focused on investing in primarily equity and junior debt tranches of collateralized loan obligations, has entered into a Purchase Agreement with certain institutional investors for the purchase and sale of approximately 11,517 shares of the Fund's 7.125% Series B Convertible Preferred Shares due August 2029 (the "Convertible Preferred Shares"), liquidation preference $1,000 ...

NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Carlyle Credit Income Fund ("we," "us," "our," "CCIF" or the "Fund") (NYSE: CCIF) today announced its financial results for its third quarter ending June 30, 2024. The full detailed presentation of the Fund's third quarter 2024 financial results can be viewed on the Fund's website carlylecreditincomefund.com/investor-dashboard. Lauren Basmadjian, CCIF's Chief Executive Officer said, "We are pleased with our progress and accomplishments during our first year as CCI ...

. Date of Issue No. of SharesDeemed Price per Share January 4, 2023 31,199 $0.168 February 7, 2023 7,789 $0.213 March 9, 2023 11,111 $0.15 April 10, 2023 16,460 $0.101 May 12, 2023 17,777 $0.093 June 9, 2023 24,691 $0.067 July 10, 2023 29,629 $0.067 August 10, 2023 35,087 $0.071 September 7, 2023 27,777 $0.09 October 10, 2023 18,018 $0.138 ● ● Carlyle Closes Unit Offering and Announces Share Issuances to Consultant August 19, 2024 6:30 PM EDT | Source: Carlyle Commodities Corp. Vancouver, British Columbia-- ...

The Carlyle Group Inc. (CG) has delayed the closing of its latest pan-Asian buyout fund. According to Bloomberg, this delay occurred as investors were increasingly directing their interest and capital into other Japan-focused funds. CG has sought an extension to finalize its sixth regional buyout fund, which was launched more than two years ago and has only managed to secure $3 billion in commitments below its initial target of $8.5 billion. Typically, raising such funds takes around 18 months. The slower-t ...

文章核心观点 - 公司Acentra Health被华盛顿商业杂志评选为"最快速增长公司"之一,这反映了公司在扩大市场份额和培养高技能员工方面的战略投资 [1][2][3][4] - 公司2021-2023年间实现了三位数的收入增长,通过两次收购扩大了客户覆盖范围,同时在人工智能、机器学习等领域进行了战略性技术投资,并大幅增加了全球员工数量 [1] - 公司获得了华盛顿商业杂志和ACG全国首都地区章的奖项,这验证了公司的成功战略 [4][6] 公司概况 - Acentra Health是一家专注于为政府医疗机构提供技术和健康解决方案的公司,致力于为重点人群加速实现更好的健康结果 [1][7] - 公司背后由全球投资公司Carlyle提供支持 [7] 业务发展 - 公司通过两次收购扩大了客户覆盖范围,现已覆盖45个州和25个联邦机构,影响了全国1.4亿受益人 [1] - 公司在人工智能、机器学习等领域进行了战略性技术投资,以提高效率并帮助解决客户重点人群的健康相关社会需求 [1] - 公司全球员工数量增长了158% [1]

文章核心观点 - 公司是一家新成立的CLO收益型封闭式基金,由著名私募基金公司Carlyle管理 [2][8] - 基金主要投资于CLO的股权和次级债券,以获取高收益 [8][9] - 基金自成立以来表现良好,总回报超过标普500指数 [2] - 基金目前持有资产超过1.05亿美元,月度分红收益率达15% [10] 基金概况 - 基金成立于2023年7月,原名为Vertical Capital Income Fund,后更名为Carlyle Credit Income Fund [2] - 基金投资目标是通过投资于CLO的股权和次级债券获取当前收益和资本增值 [8] - 作为CLO市场的主要参与者,Carlyle拥有广泛的市场关系网,有利于获取投资机会 [9] 基金投资组合 - 基金目前持有95%以上的CLO股权投资 [13] - 基金持有的CLO标的贷款加权平均评级为B+,加权平均到期期限为4.5年 [15] - 标的贷款加权平均价格在97.5-100之间,加权平均利差在3.0-3.5%之间 [15] 基金财务表现 - 基金2024年第二季度的投资收益净额有所增加,足以覆盖高收益分红 [19] - 基金净值在2024年7月31日为7.64美元,有所下降但不太令人担忧 [20] - 基金管理层表示,即使未来利率有所下降,但仍将处于较高水平,有利于CLO股权获得强劲收益 [20] 与同行对比 - 相比同类CLO收益型基金,公司表现与OXLC、ECC和OCCI相当,总回报也接近 [21] - 同行基金最近都宣布提高分红,公司也有可能跟进 [22] 总结评级 - 公司是一家值得关注的CLO收益型基金,有望继续保持良好表现 [23] - 公司有望维持或提高当前超15%的高收益分红水平 [23]